Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Макроглобулинемия Вальденстрема

Список литературы

  1. Owen R.G. et al. Clinicopathological definition of Waldenstrom’s macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia // Seminars in Oncology. W.B. Saunders, 2003. Vol. 30, № 2. P. 110–115.
  2. Kumar S.K. et al. Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). 2020.
  3. Балакирева Т.В., Андреева Н.Е. Макроглобулинемия Вальденстрема // Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2009. Vol. 2, № 2. P. 121–136.
  4. Varettoni M. et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenström’s macroglobulinemia and related lymphoid neoplasms // Blood. American Society of Hematology, 2013. Vol. 121, № 13. P. 2522–2528.
  5. Treon S.P. et al. MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia // N. Engl. J. Med. Massachussetts Medical Society, 2012. Vol. 367, № 9. P. 826–833.
  6. Morel P. et al. International prognostic scoring system for Waldenström macroglobulinemia // Blood. 2009. Vol. 113, № 18. P. 4163–4170.
  7. Kastritis E. et al. Waldenström’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Ann. Oncol. 2018. Vol. 29, № Supp. 4. P. iv41–iv50.
  8. Kastritis E. et al. Prognostication in young and old patients with Waldenström’s macroglobulinemia: Importance of the international prognostic scoring system and of serum lactate dehydrogenase // Clin. Lymphoma Myeloma. Cancer Information Group, LP, 2009. Vol. 9, № 1. P. 50–52.
  9. Демина Е.А. et al. Общие принципы диагностики лимфом // Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 9–27.
  10. Auwerda J.J.A. et al. Prothrombotic coagulation abnormalities in patients with paraprotein- producing B-cell disorders. // Clin. Lymphoma Myeloma. 2007. Vol. 7, № 7. P. 462–466.
  11. Rothschild B.M., Ruhli F., Rothschild C. Skeletal clues apparently distinguishing Waldenstrom’s macroglobulinemia from multiple myeloma and leukemia // Am. J. Hum. Biol. Wiley-Blackwell, 2002. Vol. 14, № 4. P. 532–537.
  12. Rausch P.G., Herion J.C. Pulmonary manifestations of waldenstrom macroglobulinemia // Am. J. Hematol. John Wiley & Sons, Ltd, 1980. Vol. 9, № 2. P. 201–209.
  13. Kyle R.A. et al. Prognostic markers and criteria to initiate therapy in Waldenstrom’s macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom’s Macroglobulinemia // Seminars in Oncology. W.B. Saunders, 2003. Vol. 30, № 2. P. 116–120.
  14. Owen R.G. et al. Waldenström macroglobulinemia: Development of diagnostic criteria and identification of prognostic factors // Am. J. Clin. Pathol. 2001. Vol. 116, № 3. P. 420–428.
  15. Palladini G. et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis // Circulation. Lippincott Williams and Wilkins, 2003. Vol. 107, № 19. P. 2440–2445.
  16. Menke M. et al. Ophthalmologic techniques to assess the severity of hyperviscosity syndrome and the effect of plasmapheresis in patients with Waldenström’s macroglobulinemia // Clin. Lymphoma Myeloma. Cancer Information Group, LP, 2009. Vol. 9, № 1. P. 100–103.
  17. Brandefors L. et al. Prognostic factors and primary treatment for Waldenström macroglobulinemia – a Swedish Lymphoma Registry study // Br. J. Haematol. Blackwell Publishing Ltd, 2018. Vol. 183, № 4. P. 564–577.
  18. Dimopoulos M.A. et al. Predictive factors for response to rituximab in Waldenstrom’s macroglobulinemia. // Clin. Lymphoma. 2005. Vol. 5, № 4. P. 270–272.
  19. Treon S.P. et al. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180 // J. Clin. Oncol. 2009. Vol. 27, № 23. P. 3830–3835.
  20. Ghobrial I.M. et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia // Am. J. Hematol. Wiley-Liss Inc., 2010. Vol. 85, № 9. P. 670–674.
  21. Dimopoulos M.A. et al. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide // J. Clin. Oncol. 2007. Vol. 25, № 22. P. 3344– 3349.
  22. Buske C. et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: Results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG) // Leukemia. Nature Publishing Group, 2009. Vol. 23, № 1. P. 153–161.
  23. Treon S.P. et al. Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab- containing regimen // Br. J. Haematol. 2011. Vol. 154, № 3. P. 357–362.
  24. Chen C.I. et al. Bortezomib is active in patients with untreated or relapsed Waldenström’s macroglobulinemia: A phase II study of the National Cancer Institute of Canada Clinical Trials Group // J. Clin. Oncol. 2007. Vol. 25, № 12. P. 1570–1575.
  25. Paludo J. et al. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia // Ann. Hematol. Springer Verlag, 2018. Vol. 97, № 8. P. 1417–1425.
  26. Treon S.P. et al. Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia // Blood. 2009. Vol. 113, № 16. P. 3673–3678.
  27. Laszlo D. et al. Rituximab and subcutaneous 2-chloro-2’-deoxyadenosine as therapy in untreated and relapsed Waldenström’s macroglobulinemia // Clinical Lymphoma, Myeloma and Leukemia. 2011. Vol. 11, № 1. P. 130–132.
  28. Tedeschi A. et al. Fludarabine plus cyclophosphamide and rituximab in waldenstrom macroglobulinemia: An effective but myelosuppressive regimen to be offered to patients with advanced disease // Cancer. 2012. Vol. 118, № 2. P. 434–443.
  29. Souchet L. et al. Efficacy and long-term toxicity of the rituximab-fludarabine- cyclophosphamide combination therapy in Waldenstrom’s macroglobulinemia // Am. J. Hematol. Wiley-Liss Inc., 2016. Vol. 91, № 8. P. 782–786.
  30. Kyle R.A. et al. Waldenstrom’s macroglobulinaemia: A prospective study comparing daily intermittent oral chlorambucil // Br. J. Haematol. 2000. Vol. 108, № 4. P. 737–742.
  31. Treon S.P. et al. Ibrutinib monotherapy in symptomatic, treatment-naïve patients with waldenström macroglobulinemia // J. Clin. Oncol. American Society of Clinical Oncology, 2018. Vol. 36, № 27. P. 2755–2761.
  32. Dimopoulos M.A. et al. Update on treatment recommendations from the fourth international workshop on Waldenström’s macroglobulinemia // Journal of Clinical Oncology. 2009. Vol. 27, № 1. P. 120–126.
  33. Rummel M.J. et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial // Lancet. Lancet Publishing Group, 2013. Vol. 381, № 9873. P. 1203–1210.
  34. Treon S.P. et al. Bendamustine therapy in patients with relapsed or refractory Waldenström’s macroglobulinemia // Clinical Lymphoma, Myeloma and Leukemia. 2011. Vol. 11, № 1. P. 133–135.
  35. Treon S.P. et al. Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia. Supplemental Appendix. // N. Engl. J. Med. 2015. Vol. 372, № 15. P. 1430–1440.
  36. Treon S.P. How I treat Waldenström macroglobulinemia // Blood. 2009. Vol. 114, № 12. P. 2375–2385.
  37. Балакирева Т.В., Андреева Н.Е. Макроглобулинемия Вальденстрема // Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2009. Vol. 2(2). P. 121–136.
  38. Ioakimidis L. et al. Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström’s macroglobulinemia // Clin. Lymphoma Myeloma. Cancer Information Group, LP, 2009. Vol. 9, № 1. P. 62–66.
  39. Leblond V. et al. Results of a randomized Trial of Chlorambucil versus Fludarabine for patients with untreated Waldenström Macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma // J. Clin. Oncol. 2013. Vol. 31, № 3. P. 301–307.
  40. Dimopoulos M.A. et al. Treatment of waldenstrom macroglobulinemia with 2- chlorodeoxyadenosine // Ann. Intern. Med. American College of Physicians, 1993. Vol. 118, № 3. P. 195–198.
  41. Dimopoulos M.A. et al. Treatment of Waldenstrom’s macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: Identification of prognostic factors // Ann. Oncol. 1995. Vol. 6, № 1. P. 49–52.

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*